Complete responses in advanced renal cell carcinoma: Utopia or real chance?

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 151-152

  Verzoni, Elena ^a   Garanzini, Enrico ^a   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Complete response; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; KIDNEY METASTASIS; LETTER; METASTASIS RESECTION; NEPHRECTOMY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; KIDNEY NEOPLASMS; METASTASECTOMY; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84874106859     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0765-5     Document Type: Letter

References (3)

1. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77(1):48-62.
2. Procopio G, Verzoni E, Iacovelli R, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Exp Rev Anticancer Ther. 2012;11(11):1631-40.
3. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482-7.